Idiopathic interstitial pneumonias
Conditions
Interventions
None listed
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Patients newly diagnosed with IIPs at each hospital in Japan
Exclusion criteria
Exclusion criteria: Cases that meet any of the following criteria are excluded from this study. - Patients who have difficulty cooperating with various tests required in this study, such as respiratory function tests - Patients who have undergone lobectomy or more extensive pneumonectomy by the time of registration - Patients who have not been interviewed or tested enough to diagnose IIPs by the time the central MDD diagnosis team makes a diagnosis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relative prevalence of IIPs based on MDD diagnosis | — |
Secondary
| Measure | Time frame |
|---|---|
| - Disease progression rate by IIPs classification - Cumulative survival rate by IIPs classification - Diagnostic accuracy and prognostic stratification of AI diagnostic system - Diagnostic accuracy and prognostic stratification of novel biomarkers - Cumulative incidence of acute exacerbation by IIPs classification - Cumulative incidence of connective tissue disease/vasculitis by IIPs classification - Cumulative incidence of lung cancer by IIPs classification - Changes in respiratory function by IIPs classification - Proposal-based exploratory research using this cohort data - Search for new biomarkers using stocked serum samples - Survey of end-of-life care/palliative care | — |
Countries
Japan
Contacts
Hamamatsu University School of Medicine Second Division, Department of Internal Medicine